Real-world evidence has moved from a supplementary talking point in regulatory strategy discussions to an actual component of a growing number of submissions, but its role remains narrower and more specific than the general enthusiasm around the term sometimes suggests.
The clearest accepted use case remains supporting label expansions for already-approved products, where real-world data drawn from registries, claims databases, or electronic health records can demonstrate effectiveness in populations or settings not extensively studied in the original pivotal trials. Regulators have shown more willingness to accept this kind of supplementary evidence than to rely on real-world data as the primary basis for an original approval.
External control arms built from real-world data have found a specific niche in rare disease and oncology settings, where randomizing patients to a placebo or standard-of-care arm is either impractical or raises genuine ethical concerns given a small patient population. These arms require rigorous methodology to address confounding, since patients captured in real-world databases rarely match a trial population on every relevant baseline characteristic.
Data quality remains the persistent limiting factor. Electronic health record data was not originally structured for research purposes, and inconsistent coding practices, missing data fields, and variable follow-up intervals all complicate the statistical methods needed to draw a reliable causal inference from an inherently observational dataset.
Sponsors pursuing a real-world evidence component to their regulatory strategy generally see better outcomes when they engage regulators early on the specific data source and analytical methodology, rather than generating the evidence first and seeking acceptance after the fact, since agency expectations around data provenance and statistical handling continue to evolve.
News and analysis tracking which specific real-world evidence submissions regulators have actually accepted, and on what methodological basis, rather than treating RWE as a single interchangeable category, such as the coverage from The Clinical Trial Vanguard, gives sponsors a more grounded view of where this evidence type is genuinely moving the needle today.
